Edgewise Therapeutics Statistics
Total Valuation
EWTX has a market cap or net worth of $4.80 billion. The enterprise value is $4.35 billion.
| Market Cap | 4.80B |
| Enterprise Value | 4.35B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EWTX has 108.60 million shares outstanding. The number of shares has increased by 9.70% in one year.
| Current Share Class | 108.60M |
| Shares Outstanding | 108.60M |
| Shares Change (YoY) | +9.70% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 77.24% |
| Float | 65.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.47 |
| P/TBV Ratio | 10.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.24, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.24 |
| Quick Ratio | 15.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.03% and return on invested capital (ROIC) is -26.18%.
| Return on Equity (ROE) | -38.03% |
| Return on Assets (ROA) | -25.03% |
| Return on Invested Capital (ROIC) | -26.18% |
| Return on Capital Employed (ROCE) | -48.57% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 154 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +222.01% in the last 52 weeks. The beta is 0.32, so EWTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +222.01% |
| 50-Day Moving Average | 39.27 |
| 200-Day Moving Average | 30.42 |
| Relative Strength Index (RSI) | 56.73 |
| Average Volume (20 Days) | 1,099,980 |
Short Selling Information
The latest short interest is 10.07 million, so 9.28% of the outstanding shares have been sold short.
| Short Interest | 10.07M |
| Short Previous Month | 10.49M |
| Short % of Shares Out | 9.28% |
| Short % of Float | 15.46% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -218.90M |
| Pretax Income | -197.22M |
| Net Income | -197.22M |
| EBITDA | -216.56M |
| EBIT | -218.90M |
| Earnings Per Share (EPS) | -$1.85 |
Balance Sheet
The company has $460.71 million in cash and $3.59 million in debt, with a net cash position of $457.12 million or $4.21 per share.
| Cash & Cash Equivalents | 460.71M |
| Total Debt | 3.59M |
| Net Cash | 457.12M |
| Net Cash Per Share | $4.21 |
| Equity (Book Value) | 448.08M |
| Book Value Per Share | 4.16 |
| Working Capital | 442.48M |
Cash Flow
In the last 12 months, operating cash flow was -$158.38 million and capital expenditures -$454,000, giving a free cash flow of -$158.83 million.
| Operating Cash Flow | -158.38M |
| Capital Expenditures | -454,000 |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -158.83M |
| FCF Per Share | -$1.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EWTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.70% |
| Shareholder Yield | -9.70% |
| Earnings Yield | -4.19% |
| FCF Yield | -3.38% |
Analyst Forecast
The average price target for EWTX is $50.85, which is 14.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $50.85 |
| Price Target Difference | 14.97% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |